Indeed, given that cardiac sympathetic dysfunction has previously been linked to arrhythmias and HF, both of which are frequently experienced by patients, understanding the time- and dose-dependency of DOXO effects on cSNs is key for refining therapy (including β-AR blockers and neuromodulation) to prevent such adverse consequences. The gene discussed is ADRB2; the disease is Arrhythmia.